Captor Therapeutics Spolka Akcyjna (WSE: CTX)
Health Care · Biotechnology · PL
zł72.00
-1.37% today · +71.8% 1Y
Captor Therapeutics Spolka Akcyjna (WSE: CTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $125.60M and employs 82 people.
Over the last twelve months the share price has gained 71.8%, trading between 33.00 and 89.20.
Tweenvest scores Captor Therapeutics Spolka Akcyjna across four factors: quality 18/100, value 55/100. Its strongest factor is value.
CTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $125.60M
- Revenue (TTM)
- $639.33K
- P/E
- —
- EPS
- -7.71
- Dividend yield
- —
- Beta (5Y)
- 0.55
- 52-week high
- zł89.20
- 52-week low
- zł33.00
- Avg volume (3M)
- —
- Shares outstanding
- 6.35M
- Employees
- 82
- Next earnings
- —
About Captor Therapeutics Spolka Akcyjna
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
- ISIN
- PLCPTRT00014
- Founded
- 2015
- Listed since
- Apr 20, 2021
- Exchange
- Warsaw Stock Exchange
- Currency
- PLN
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.77 | +2.07% |
Figures last refreshed Aug 18, 2026.